Dsm International B.V.
recently revealed that they own a 36.7% stake in Amyris, Inc. (NASDAQ:AMRS) in a Form 13D/A disclosure that was filed with the Securities and Exchange Commission on Wednesday, August 9th. The investor owns 16,621,192 shares of the stock valued at about $40,057,073. The reporting parties listed on the disclosure included DSM International BV and Koninklijke DSM NV. The disclosure is available through Edgar at this link.
Dsm International B.V.
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Separately, Bank of New York Mellon Corp increased its position in shares of Amyris by 16.3% in the second quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock worth $104,000 after buying an additional 4,603 shares during the last quarter.
Shares of Amyris, Inc. (NASDAQ:AMRS) traded up 19.31% during trading on Friday, reaching $2.41. The company had a trading volume of 764,244 shares. The firm’s 50 day moving average price is $3.34 and its 200 day moving average price is $5.58. Amyris, Inc. has a 12 month low of $1.86 and a 12 month high of $18.15. The firm’s market capitalization is $90.63 million.
Amyris (NASDAQ:AMRS) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by $0.35. The company had revenue of $25.68 million during the quarter, compared to analysts’ expectations of $23.68 million. During the same quarter in the prior year, the firm posted ($0.06) earnings per share. The business’s quarterly revenue was up 167.5% compared to the same quarter last year. Equities analysts predict that Amyris, Inc. will post ($3.32) EPS for the current year.
WARNING: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2017/08/19/36-7-stake-of-amyris-inc-amrs-maintained-by-dsm-international-b-v-updated.html.
A number of brokerages recently commented on AMRS. Cowen and Company set a $4.00 price objective on Amyris and gave the stock a “hold” rating in a research report on Thursday. HC Wainwright set a $15.00 price objective on Amyris and gave the stock a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research upgraded Amyris from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, ValuEngine downgraded Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Amyris currently has a consensus rating of “Hold” and an average target price of $25.70.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
What are top analysts saying about Amyris Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amyris Inc. and related companies.